Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc. | SPY001 | Inflammatory Bowel Disease (IBD) | Phase 2 | Trial Planned | Intravenous | Gastroenterology |
| Stoke Therapeutics Inc. | Zorevunersen (STK-001) - (EMPEROR) | Dravet syndrome | Phase 3 | Ongoing | Intrathecal | Neurology |
| Structure Therapeutics Inc. | Aleniglipron (GSBR-1290) - (ACCESS and ACCESS II ) | Type 2 Diabetes, obesity | Phase 2b | Data Released | oral | Endocrinology |
| Summit Therapeutics Inc. | Ivonescimab plus platinum-doublet chemotherapy - (HARMONi) | EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) | BLA Filing | Ongoing | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ivonescimab plus platinum-doublet chemotherapy - (HARMONi) | EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) | BLA Filing | Ongoing | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ridinilazole - (Ri-CoDIFy) | C. difficile infection (CDI) | Phase 3 | Ongoing | Oral | Gastroenterology |
| Summit Therapeutics Inc. | Ivonescimab - (HARMONi-GI3) | Colorectal cancer (CRC) | Phase 3 | Trial Planned | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ivonescimab with platinum-based chemotherapy compared with tislelizumab - (AK112-306/HARMONi-6) | Locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression | Phase 3 | Data Released | Intravenous | Oncology |
